Literature DB >> 9029664

Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments.

F Van Hunsel1, A Wauters, E Vandoolaeghe, H Neels, P Demedts, M Maes.   

Abstract

Strong evidence has recently been reported that major depression is accompanied by an acute phase response (APR), characterized by elevated levels of positive acute phase proteins (APPs) and decreased levels of negative APPs. The APR is also reflected in lowered total serum protein (TSP) and specific changes in the major electrophoretically separated protein fractions. The present study examined pretreatment and posttreatment serum TSP and the concentrations and percentages of the major electrophoretically separated serum protein fractions in 37 major depressed subjects, of whom 29 had treatment-resistant depression (TRD), and in 29 normal controls. We found that TSP and the percentage and concentration of serum albumin (Alb) and gamma-globulin fraction were significantly lower in major depression and TRD than in normal controls. Serum beta-globulin concentrations were significantly lower in major depressed and TRD subjects than in normal controls. The percentages of the alpha 1- and alpha 2-globulin fractions were significantly higher in major depressed subjects than in normal controls. There were no significant effects of subchronic treatment with antidepressants on TSP, the percentage or concentration of the major electrophoretically separated protein fractions, i.e. alpha 1-, alpha 2- and beta-globulin. There was a significant increase in percentage of the gamma-globulin fraction after subchronic treatment with antidepressants. The results support the hypothesis that major depression and TRD are accompanied by a chronic APR.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9029664     DOI: 10.1016/s0165-1781(96)03010-7

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Immune-inflammatory, oxidative stress and biochemical biomarkers predict short-term acute ischemic stroke death.

Authors:  Edna Maria Vissoci Reiche; Jair Roberto Gelinksi; Daniela Frizon Alfieri; Tamires Flauzino; Marcio Francisco Lehmann; Maria Caroline Martins de Araújo; Marcell Alysson Batisti Lozovoy; Andrea Name Colado Simão; Elaine Regina Delicato de Almeida; Michael Maes
Journal:  Metab Brain Dis       Date:  2019-03-14       Impact factor: 3.584

2.  ROS-Targeted Depression Therapy via BSA-Incubated Ceria Nanoclusters.

Authors:  Shengyang Fu; Huili Chen; Weitao Yang; Xiaohuan Xia; Shu Zhao; Xiaonan Xu; Pu Ai; Qingyuan Cai; Xiangyu Li; Yi Wang; Jie Zhu; Bingbo Zhang; Jialin C Zheng
Journal:  Nano Lett       Date:  2022-05-18       Impact factor: 12.262

3.  Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.

Authors:  Enrico Domenici; David R Willé; Federica Tozzi; Inga Prokopenko; Sam Miller; Astrid McKeown; Claire Brittain; Dan Rujescu; Ina Giegling; Christoph W Turck; Florian Holsboer; Edward T Bullmore; Lefkos Middleton; Emilio Merlo-Pich; Robert C Alexander; Pierandrea Muglia
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

4.  Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability.

Authors:  Sinan Guloksuz; Marieke Wichers; Gunter Kenis; Maurice G V M Russel; Annick Wauters; Robert Verkerk; Baer Arts; Jim van Os
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

5.  Antidepressant drug-protein interactions studied by spectroscopic methods based on fluorescent carbon quantum dots.

Authors:  Sandeep K Vaishanav; Toshikee Yadav; Srishti Sinha; Swapnil Tiwari; Manmohan L Satnami; Kallol K Ghosh
Journal:  Heliyon       Date:  2019-05-10

6.  Associations of decreased serum total protein, albumin, and globulin with depressive severity of schizophrenia.

Authors:  Xu Yuan Yin; Yuan Cai; Zhen Hua Zhu; Chang Ping Zhai; Jian Li; Cai Fang Ji; Peng Chen; Jing Wang; Yi Ming Wu; Raymond C K Chan; Qiu Fang Jia; Li Hui
Journal:  Front Psychiatry       Date:  2022-07-25       Impact factor: 5.435

7.  Elevated stress-hemoconcentration in major depression is normalized by antidepressant treatment: secondary analysis from a randomized, double-blind clinical trial and relevance to cardiovascular disease risk.

Authors:  Ma-Li Wong; Chuanhui Dong; Karin Esposito; Sarika Thakur; Weiqing Liu; Robert M Elashoff; Julio Licinio
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

8.  A Meta-Analysis of Oxidative Stress Markers in Depression.

Authors:  Tao Liu; Shuming Zhong; Xiaoxiao Liao; Jian Chen; Tingting He; Shunkai Lai; Yanbin Jia
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 9.  Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness.

Authors:  Michael Berk; Olivia Dean; Hemmo Drexhage; John J McNeil; Steven Moylan; Adrienne O'Neil; Christopher G Davey; Livia Sanna; Michael Maes
Journal:  BMC Med       Date:  2013-03-18       Impact factor: 8.775

10.  Common mechanisms of pain and depression: are antidepressants also analgesics?

Authors:  Tereza Nekovarova; Anna Yamamotova; Karel Vales; Ales Stuchlik; Jitka Fricova; Richard Rokyta
Journal:  Front Behav Neurosci       Date:  2014-03-25       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.